ѱ̿Ǿǰȸ Ʈ
|
|
|
ɰ ӿ 2017 ۷ι ̿ ۷ Ƚϴ.
ֽ е鲲 帳ϴ. |
|
|
GBC 2017, ѱ̿Ǿǰȸ Ȩ Ʃ꿡 ٽ ֽϴ. |
|
|
GBC 2017 ¶ 7 10 () Ͻ ֽϴ. |
|
|
|
|
ڷ |
4 ߽, ̿Ǿǰ Ѵ
ǰǾǰó(ó չ) 4 ߽, ̿Ǿǰ 2017 ۷ι ̿ ۷ 6 26Ϻ 6 30ϱ ƼŻ ڿ ȣ( ) ֵǾ.
̹ 3ȸ° 츮 ̿Ǿǰ ̷ ַ» ϰ, ۷ι ϱ Ͽ ̿Ǿǰ о 籹ڵ ‧ ϱ õǾ.
- Ư ش 翡 ռ 츮 ÷ܹ̿Ǿǰ ż ǰȭ ε ̱ Ͽ Ưڹ 4 ̿Ǿǰ ҡ ް ȭϴ ȯ ӿ ̿Ǿǰ ̷ ľó ҿ ϴ ð ǹ̸ ߴ.
̹ ۷ ֿ䳻 㱹 û Ư , ġ ̿Ǿǰ оߺ 㱹 ǰ Ư ̴.
ľó ̹ ۷ 츮 ̿Ǿǰ ̿Ǿǰ ߽ ϴ Ⱑ ̶, ۷ ۷ι ̽ İ ϴ ÿ ȭ ִ ȹ̶ ߴ.
....... |
|
|
ڷ |
ʼǾǰ ȭ Ƿ ȭ
- , ʼǾǰ 17 ߰ -
(, ľó, , ξó, , Ǻ, 뵿, ó, ڷ¾ȸ) ÷翣 ġ ڳ̺ ĸ 17 ǰ ʼǾǰ ߰ Ͽ 126 ǰ ʼǾǰ ϰ Ǿٰ .
ľó ʼǾǰ Ǿǰ ġ 㱹ʼǾǰ ǹȸ ߴ Ǿǰ Ưʼ, ߴ ؼ å Ͽ.
ľó ε ߺ żϰ ϰ Ƿ忡 ȯ ġῡ ʼ Ǿǰ ǵ ּ ϰڴٰ ........... |
|
ڷ |
2017 Ϲݱ Ǿǰ å
Ƿǰ оߴ Ǿǰ ǰ (7) ϹǾǰ ܺ ǥ б (12) ص Ƿ ü (12) ȴ........
ľó ΰǰ ȣ Ͽ õ ȭϴ ÿ ϴ ϰڴٰ . |
|
Թ |
ü Ϻΰ Թ
1.
㰡 ڰ ִ ǥ Ǵ ϴ Ÿ Ϻ ̺ ,Ϸ
2. ֿ䳻
. ̽ ռ θ ˻ϰ Ȯ ƴ ϵ ( 101, 2511ȣ).
. ִ ǥ Ǵ ż( 155, 344ȣ2)
. ⱹ ( 172)
3. ǰ
ü Ϻΰȿ Ͽ ǰ ִ ü Ǵ 2017 8 9ϱ Թý Ͽ ¶ ǰ Ͻðų, ǰ ǰǾǰó(̿Ǿǰå) Ͽ ֽñ ٶϴ......... |
|
˸ |
ǰɻ, ž ء ˸
ֿ
1.7. Ƿῡ ġ Ͽ ʿ 쿡 []
- ġ ó ż (5/12 )
2.8. (д) []
- 2.8.3. İ д ó
ǰ : '17. 06. 28()
ȸ Ȩ ȮϽñ ٶϴ........ |
|
|
|
|
|
û |
|
ǰ |
ӻ |
ܰ |
()Ƽ̿ |
20170626 |
༺ ȯڿ ǰ Ÿ ڿؼ ӻ1
|
1 |
SMT-NK |
ѱķֽȸ |
20170627 |
༺ Ǽ Ͽ 뷮 Durvalumab + Tremelimumab Ǵ Durvalumab ܵ , ٱ, ӻ (STRONG) |
3b |
MEDI4736
MEDI1123 |
ѱ() |
20170627 |
༺ ȯڸ ܵ pembrolizumab MK-4280 ϴ 1 ӻ |
1 |
MK-4280
Pembrolizumab |
ѱ() |
201706278 |
Ǵ ȣŲ ȯڸ Pembrolizumab Brentuximab Vedotin ϴ III, , - ӻ |
3 |
MK-3475 |
Zﺴ |
20170628 |
Etoposide+cisplatin ̼ - (GEP) Ű泻к (NEC, WHO 3) ġμ avelumab II ӻ: Ȯϱ ü м |
2 |
MSB0010718C |
ѱƼ() |
20170629 |
Ȱ Ǽ ȯڿ secukinumab ܵ adalimumab ܵ 52
ȿ Ͽ ϱ , -, Ȱ , ٱ ӻ
|
3b |
AIN457 |
|
|
|
|
|
|
|
|
FDA |
|
Drug Name and
FDA Appl. # |
Active Ingredients |
Submission
Classification |
Company |
Approval Date |
TRIPTODUR
NDA #208956 |
TRIPTORELIN |
Ǵ
|
ARBOR PHARMS INC |
06/29/2017 |
EFAVIRENZ, LAMIVUDINE,
AND TENOFOVIR DISOPROXIL FUMARATE
NDA #204119 |
EFAVIRENZ
LAMIVUDINE
TENOFOVIR DISOPROXIL FUMARATE |
ſ뷮 |
HETERO DRUGS LTD |
06/30/2017 |
PANTOPRAZOLE SODIUM
NDA #209463 |
PANTOPRAZOLE SODIUM |
Ǵ
|
EXELA PHARMA
SCS LLC |
06/30/2017 |
|
|
|
|
EMA |
|
Name |
Active Substance |
Therapeutic areaCompany |
Date of authorisation
/refusal |
Ucedane |
carglumic acid |
Amino Acid Metabolism, Inborn Errors
Hyperammonemia |
23/06/2017 |
Kevzara |
sarilumab |
Arthritis, Rheumatoid |
23/06/2017 |
Erelzi |
etanercept |
Arthritis, Juvenile Rheumatoid
Arthritis, Psoriatic
Arthritis, Rheumatoid
Psoriasis |
23/06/2017 |
|
|
|
|
|
|
|
Clinical.gov ̱ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03206073 |
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer |
Colorectal Cancer
Microsatellite-
Stable (MSS) Tumor
Metastatic Disease |
Drug: Durvalumab
Drug: Tremelimumab
Biological: Pexa-Vec |
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC) |
Phase 1
Phase 2 |
NCT03206047 |
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma |
Drug: Atezolizumab
Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Drug: Guadecitabine
Other: Laboratory Biomarker Analysis
Drug: Poly ICLC |
National Cancer Institute (NCI) |
Phase 1
Phase 2 |
NCT03205644 |
VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors |
Recurrent Malignant Solid Neoplasm
Recurrent Osteosarcoma
Refractory Malignant Solid Neoplasm |
Biological: Anti-SEMA4D Monoclonal Antibody VX15/2503
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study |
Children's Oncology Group
National Cancer Institute (NCI)
COG Phase
Consortium |
Phase 1
Phase 2 |
NCT03207542 |
Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL) |
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic |
Drug: Daratumumab |
M.D. Anderson Cancer Center
Janssen Scientific Affairs, LLC |
Phase 2 |
NCT03205891 |
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas |
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic|Classical Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma|CD30+ Peripheral T-cell Lymphoma |
Drug: Brentuximab Vedotin
Drug: TAK228
Device: Glucose Monitor |
M.D. Anderson Cancer Center
Takeda |
Phase 1 |
NCT03202628 |
Ixazomib Citrate, Pomalidomide, Dexamethasone, and Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Multiple Myeloma |
Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma |
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Dexamethasone
Drug: Ixazomib Citrate
Other: Laboratory Biomarker Analysis
Drug: Pomalidomide |
Mayo Clinic|National Cancer Institute (NCI) |
Phase 2 |
NCT03203304 |
Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma |
Hepatocellular Carcinoma |
Drug: Nivolumab
Drug: Ipilimumab |
University of Chicago |
Phase 1 |
|
|
|
|
Clinical.gov |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03203421 |
A Safety and Efficacy Study of ChAdOx1 LS2 |
Malaria |
Biological: ChAdOx1 LS2 |
University of Oxford |
Phase 1
Phase 2 |
NCT03202368 |
An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA) |
Giant Cell Arteritis |
Drug: Tocilizumab |
Hoffmann-La Roche |
Phase 3 |
|
|
|
|
|
Clinical.gov ߱ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03205930 |
Neo-MASCT Immunotherapy for Advanced NSCLC |
NSCLC Stage IV
|
Biological:
Neo-MASCT |
The First People's Hospital of Lianyungang
HengRui YuanZheng Bio-Technology Co.,Ltd. |
Phase 1
Phase 2 |
|
|
|
|
Clinical.gov Ϻ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03203876 |
A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors |
Advanced Cancer |
Biological: Lirilumab
Biological: Nivolumab
Biological: Ipilimumab |
Bristol-Myers Squibb
Ono Pharmaceuticals |
Phase 1 |
|
|
|
|
|
|
|
̿IT÷ '17 ű ȳ |
̿IT÷ 2017 ű |
2017 Ͽ 12 ܿ Ʈ, εþ, Űź 3 ߰ Դϴ. ɰ ̿ Ź 帳ϴ. |
|
̿IT÷ ȳ |
2017 ֿ ǿ(̱, , ߱) ü 㰡 (2017 ÷ܹ̿Ǿǰ ؿ ̿IT÷ ) Ӱ ǽ Դϴ. û ٶϴ. |
'' ̶? |
̿Ǿǰ ؿ 㰡 ִ
1:1(ñ: Ƿ ü) |
|
|
Ͻô ü ȸ Ǵ ̿IT÷ Ȩ ̿IT÷ û ȮϽð,
̿Ǿǰ ؿ Ƿڼ ۼϽþ ̸(bpis@kobia.kr) ûϽñ ٶϴ.
ִ 5 ȭ, (ܰ躰) Ƿڰ մϴ. |
|
̿IT÷ () ٷΰ |
|
̿IT÷ ٷΰ |
|
|
|
|
|
|
|
|
|
|
|
Global Bio Conference 2017 ϰ Ǿϴ.
ֺʹ ѱ̿ǾǰͰ ڿԸ ǿ,
ѱ̿Ǿǰȸ Ͻø info@kobia.kr Ű Ͻñ ٶϴ. մϴ. |
|
|
|
|
|
|